India’s rare disease market is on the rise, expected to grow from $2.74 billion to $6.6 billion by 2030. However, challenges such as delayed diagnoses, limited treatment accessibility and underutilized government funds continue to impact patient outcomes.
This article from explores the current landscape of rare disease management in India, highlighting key policies like the National Policy for Rare Diseases (NPRD) 2021, advancements in research and government initiatives supporting treatment accessibility. It also uncovers untapped opportunities for pharmaceutical companies to drive innovation and expand access.
Download the full whitepaper to discover how industry leaders can collaborate with policymakers, healthcare providers and patient advocacy groups to transform rare disease care in India.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…